{
    "id": 23288,
    "fullName": "EGFR H773Y",
    "impact": "missense",
    "proteinEffect": "unknown",
    "geneVariantDescriptions": [
        {
            "description": "EGFR H773Y lies within the protein kinase domain of the Egfr protein (UniProt.org). H773Y has been identified in the scientific literature (PMID: 15753462, PMID: 19536777, PMID: 23139256), but has not been biochemically characterized and therefore, its effect on Egfr protein function is unknown (PubMed, Oct 2019).",
            "references": [
                {
                    "id": 8109,
                    "pubMedId": 19536777,
                    "title": "Second-line treatments after first-line gefitinib therapy in advanced nonsmall cell lung cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/19536777"
                },
                {
                    "id": 8100,
                    "pubMedId": 23139256,
                    "title": "Aberrations in the epidermal growth factor receptor gene in 958 patients with diverse advanced tumors: implications for therapy.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23139256"
                },
                {
                    "id": 285,
                    "pubMedId": null,
                    "title": null,
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed"
                },
                {
                    "id": 295,
                    "pubMedId": null,
                    "title": null,
                    "url": "https://www.uniprot.org"
                },
                {
                    "id": 8108,
                    "pubMedId": 15753462,
                    "title": "Phase I/II trial evaluating the anti-vascular endothelial growth factor monoclonal antibody bevacizumab in combination with the HER-1/epidermal growth factor receptor tyrosine kinase inhibitor erlotinib for patients with recurrent non-small-cell lung cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/15753462"
                }
            ]
        }
    ],
    "type": null,
    "gene": {
        "id": 1956,
        "geneSymbol": "EGFR",
        "terms": [
            "EGFR",
            "ERBB",
            "ERBB1",
            "HER1",
            "mENA",
            "NISBD2",
            "PIG61"
        ]
    },
    "variant": "H773Y",
    "createDate": "06/16/2016",
    "updateDate": "10/06/2019",
    "referenceTranscriptCoordinates": {
        "id": 135682,
        "transcript": "NM_005228",
        "gDna": "chr7:g.55181326C>T",
        "cDna": "c.2317C>T",
        "protein": "p.H773Y",
        "sourceDb": "RefSeq",
        "refGenomeBuild": "GRCh38/hg38"
    },
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 16280,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells expressing EGFR H773Y were resistant to treatment with Rocelitinib (CO-1686) in culture (PMID: 29141884).",
            "molecularProfile": {
                "id": 23968,
                "profileName": "EGFR H773Y"
            },
            "therapy": {
                "id": 1003,
                "therapyName": "Rociletinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 10358,
                    "pubMedId": 29141884,
                    "title": "A method of high-throughput functional evaluation of EGFR gene variants of unknown significance in cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29141884"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 16278,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells expressing EGFR H773Y were sensitive to treatment with Tagrisso (osimertinib) in culture, demonstrating reduced cell viability (PMID: 29141884).",
            "molecularProfile": {
                "id": 23968,
                "profileName": "EGFR H773Y"
            },
            "therapy": {
                "id": 660,
                "therapyName": "Osimertinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10358,
                    "pubMedId": 29141884,
                    "title": "A method of high-throughput functional evaluation of EGFR gene variants of unknown significance in cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29141884"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 16281,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells expressing EGFR H773Y were resistant to treatment with Erbitux (cetuximab) in culture (PMID: 29141884).",
            "molecularProfile": {
                "id": 23968,
                "profileName": "EGFR H773Y"
            },
            "therapy": {
                "id": 694,
                "therapyName": "Cetuximab",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 10358,
                    "pubMedId": 29141884,
                    "title": "A method of high-throughput functional evaluation of EGFR gene variants of unknown significance in cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29141884"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 16279,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells expressing EGFR H773Y were resistant to treatment with Tarceva (erlotinib) in culture (PMID: 29141884).",
            "molecularProfile": {
                "id": 23968,
                "profileName": "EGFR H773Y"
            },
            "therapy": {
                "id": 4,
                "therapyName": "Erlotinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 10358,
                    "pubMedId": 29141884,
                    "title": "A method of high-throughput functional evaluation of EGFR gene variants of unknown significance in cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29141884"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 16277,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells expressing EGFR H773Y were sensitive to treatment with Gilotrif (afatinib) in culture, demonstrating reduced cell viability (PMID: 29141884).",
            "molecularProfile": {
                "id": 23968,
                "profileName": "EGFR H773Y"
            },
            "therapy": {
                "id": 623,
                "therapyName": "Afatinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10358,
                    "pubMedId": 29141884,
                    "title": "A method of high-throughput functional evaluation of EGFR gene variants of unknown significance in cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29141884"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 23968,
            "profileName": "EGFR H773Y",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        {
            "id": 135682,
            "transcript": "NM_005228",
            "gDna": "chr7:g.55181326C>T",
            "cDna": "c.2317C>T",
            "protein": "p.H773Y",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        }
    ]
}